Company intelligence / Profile preview
Bivision Pharmaceuticals
Nanjing, Jiangsu, China
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
The lead candidate, JH02 (Lutetium Lu177-labeled small molecule targeting PSMA), has received IND approval from both the US FDA and China’s NMPA. It is currently in Phase I/II trials for mCRPC. Preclinical data suggest improved efficacy over existing therapies like Pluvicto, especially across a broader range of PSMA expression levels. Additional programs are at earlier stages targeting solid tumors with both therapeutic and diagnostic applications.[1][2][7]
- Therapeutic areas
- Oncology
- Modalities
- Targeted radiopharmaceuticals (Targeted Radionuclide Therapy)Small moleculesPeptides[1][2][4]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Bivision Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bivision Pharmaceuticals.